Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRE | P78334 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.32 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.32 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL28967597 | 0.96 | HPGD (0.39) | HPGDCYP3A4NAMPTXDHGABRA1 | |
| Butyl Formate SCHEMBL28320805 | 0.76 | NPC1 (0.33) | MAPTLMNAPOLBGRIN2DGRIN3B | |
| SCHEMBL8023464 | 0.76 | — | — | |
| SCHEMBL18529294 | 0.76 | — | — | |
| SCHEMBL10399828 | 0.76 | — | — | |
| SCHEMBL3582886 | 0.76 | — | — | |
| SCHEMBL2427435 | 0.76 | — | — | |
| SCHEMBL4255025 | 0.76 | — | — | |
| SCHEMBL2544544 | 0.76 | — | — | |
| SCHEMBL10002534 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042859-A1 | METHOD FOR PREPARING 3,5-DINITROPYRAZOLE | EURENCO (FR) | 2025-02-06 | — | — | US | claimed |
| EP-4448496-A1 | METHOD FOR PREPARING 3,5-DINITROPYRAZOLE | ArianeGroup SAS (FR) | 2024-10-23 | — | — | EP | claimed |
| CN-117903454-A | NEMOFs material containing bisoxazole ligand and preparation method thereof | 湖北航天化学技术研究所 | 2024-04-19 | — | — | CN | claimed |
| CN-115894453-B | Pyrazole compound, energetic ionic salt thereof and preparation method thereof | 南京理工大学 | 2024-04-02 | — | — | CN | claimed |
| CN-116970180-A | Double-ligand energetic metal complex and preparation method thereof | 北京理工大学 | 2023-10-31 | — | — | CN | claimed |
| WO-2023111472-A1 | METHOD FOR PREPARING 3,5-DINITROPYRAZOLE | ARIANEGROUP SAS (FR) | 2023-06-22 | — | — | WO | claimed |
| CN-116041340-A | 3-amino-4- (4-amino-5-hydrazino-1, 2, 4-triazol-3-yl) furazan and energetic ionic salts thereof | 南京理工大学 | 2023-05-02 | — | — | CN | claimed |
| CN-115894453-A | Imidazole compound, energetic ionic salt thereof and preparation method | 南京理工大学 | 2023-04-04 | — | — | CN | claimed |
| EP-3555622-B1 | METHODS AND SYSTEMS FOR QUANTITATIVE IMMUNOHISTOCHEMISTRY | VENTANA MED SYST INC (US) | 2023-02-22 | — | — | EP | claimed |
| CN-110256350-B | Pyrazole ligand, zero-dimensional functional complex, preparation method and application thereof | 郑州大学 | 2022-10-11 | — | — | CN | claimed |
| CN-103980199-B | The preparation method of amino-3, the 5-binitropyrazoles of 1- | INST. OF CHEMICAL MATERIAL, CHINESE INST. OF ENGINEERING PHYSICS (CN) | 2016-03-16 | — | — | CN | claimed |
| EP-2155688-B1 | DINITROPYRAZOLE DERIVATIVES, THEIR PREPARATION, AND ENERGETIC COMPOSITIONS COMPRISING THEM. | HERAKLES (FR) | 2015-08-05 | — | — | EP | claimed |
| CN-103980199-A | Preparation method of 1-amino-3, 5-dinitryl pyrazol | INST CHEMICAL MATERIAL CHINA ACADEMY ENGINEERING PHYSICS | 2014-08-13 | — | — | CN | claimed |
| US-8273784-B2 | Dinitropyrazole derivatives, their preparation, and energetic compositions comprising them | HERAKLES (FR) | 2012-09-25 | — | — | US | claimed |
| EP-2130821-B1 | Derivatives of 3,4,5-trinitropyrazole, their preparation and the energetic compositions containing them | SME (FR) | 2011-09-21 | — | — | EP | claimed |
| EP-2155688-A2 | DINITROPYRAZOLE DERIVATIVES, THEIR PREPARATION, AND ENERGETIC COMPOSITIONS COMPRISING THEM. | SNPE Matériaux Energétiques (FR) | 2010-02-24 | — | — | EP | claimed |
| EP-2130821-A1 | Derivatives of 3,4,5-trinitropyrazole, their preparation and the energetic compositions containing them | SNPE Matériaux Energétiques (FR) | 2009-12-09 | — | — | EP | claimed |
| US-20090186931-A1 | Dinitropyrazole derivatives, their preparation, and energetic compositions comprising them | ARIANEGROUP SAS (FR) | 2009-07-23 | — | — | US | claimed |
| WO-2008152525-A2 | DINITROPYRAZOLE DERIVATIVES, THEIR PREPARATION, AND ENERGETIC COMPOSITIONS COMPRISING THEM. | SNPE MATERIAUX ENERGETIQUES (FR) | 2008-12-18 | — | — | WO | claimed |
| US-4300962-A | Ammonium nitrate explosive systems | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1981-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042859-A1 | METHOD FOR PREPARING 3,5-DINITROPYRAZOLE | AP3S1, CYP3A43, CYP3A7 | HPGD 669/4885CYP3A4 15/4885NAMPT 61/4885 |
| US-20090186931-A1 | Dinitropyrazole derivatives, their preparation, and energetic compositions comprising them | NQO2, HRH4, NFE2L2 | HPGD 120/4885CYP3A4 486/4885NAMPT 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.